Mounjaro weight loss stories: what the clinical evidence tells us

Step 1, Understanding what the trial populations actually looked like

The SURMOUNT-1 trial randomised 2,539 adults with obesity or overweight plus at least one weight-related condition. Participants followed a reduced-calorie diet and increased physical activity alongside their injections, a design that reflects how the medicine is intended to be used in real life. The 72-week duration matters: most weight loss occurred in the first 36 weeks, then continued at a slower pace. At the 15 mg dose, average reduction reached roughly 20–21% of starting body weight. At 10 mg it was around 19%, and at 5 mg around 15%. These are averages across hundreds of people, so individual results sat above and below those figures.

A separate head-to-head study, SURMOUNT-5, compared tirzepatide directly with semaglutide 2.4 mg over 72 weeks in adults without diabetes. Tirzepatide produced greater average weight loss. That trial, published in 2025, informed NICE's updated assessment of tirzepatide (TA1026).

One thing the data cannot tell you is what you personally will lose. Starting BMI, metabolic history, whether you have type 2 diabetes, and how consistently you use the medicine all influence outcomes. Our clinical team, whose profiles you can read on the clinical team page, discusses this in every consultation.

Step 2 (How the medicine creates those results

Tirzepatide is a dual GIP and GLP-1 receptor agonist) the only medicine of its kind licensed in the UK. Activating both receptors amplifies signals that tell the brain food has arrived, slows the stomach's emptying rate, and reduces appetite more consistently across the day than appetite fluctuation usually allows. The result is that many people on treatment find they eat less without feeling deprived, and food preoccupation (the background mental noise about eating) often quietens.

Treatment starts at 2.5 mg, a tolerability dose designed to let the body adjust before the dose increases. Most people move up in 4-week steps, guided by their prescriber, reaching the dose at which they get adequate benefit with manageable side effects. For a fuller picture of how tirzepatide works, our tirzepatide overview covers the mechanism in more detail.

The most commonly reported side effects are gastrointestinal: nausea, loose stools, indigestion and, less often, vomiting. These are usually most noticeable after a new dose starts and settle over days to a couple of weeks for most people. The NHS tirzepatide page lists the full side-effect profile alongside guidance on when to seek help.

Step 3, What happens when treatment ends

This is the question that tends to follow once people have read the headline trial figures. SURMOUNT-4, a follow-up study, found that people who stopped tirzepatide after 36 weeks regained a significant portion of the weight they had lost over the subsequent year, while those who continued maintained their results. The biology explains this: the appetite and metabolic signals that Mounjaro modifies return to their pre-treatment pattern when the medicine is no longer present.

That does not mean treatment is indefinitely required for everyone, but it does mean that stopping is a clinical decision, not simply a personal one. If you have read accounts of people who have stopped Mounjaro, you will notice that the most sustainable outcomes tend to involve a gradual taper, lifestyle habits that are genuinely embedded, and a prescriber who monitors what happens next.

Understanding the cost of continuing treatment over time is part of that picture. If you want to see what private treatment typically costs month to month, our Mounjaro pricing page sets out the context honestly, including what a legitimate private price covers.

Step 4, Reading weight loss stories critically

Personal weight loss accounts spread quickly online, and most are genuine. But they carry selection bias almost by definition: people who lost five stone tend to post; people who lost two and stopped do not. The 20% average in SURMOUNT-1 is meaningful precisely because it captures everyone in the trial, including those who lost less.

Something else worth knowing: the trial participants used Mounjaro alongside structured diet and activity support. Real-world results, across diverse people with different starting points and levels of lifestyle support, are variable. A question our prescribers hear regularly is whether the stories online reflect what to expect. The honest answer is that they reflect the upper range, and that reading Mounjaro stories from people at different stages of treatment gives useful context, while a clinical assessment provides a much more grounded view of your likely starting point. For a broader look at what weight loss on Mounjaro involves, including the lifestyle element, that page covers it in full.

If you are considering treatment and want to understand the full Mounjaro picture before deciding, our main Mounjaro page brings together eligibility, the process and what to expect. When you are ready, checking your eligibility takes a few minutes and is reviewed the same day by a named GPhC-registered prescriber.